Macular Degeneration Treatment: Advances, Options, and the Market Outlook

ganeshsak901

posted on 3 days ago — updated on 1 second ago

6
views

Macular degeneration treatment market is expected to gain market growth in the forecast period of 2021-2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6.80% in the above mentioned forecast period and expected to reach the USD of 13108.05 million by 2028.

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among individuals over 50, especially in developed countries. As the aging population grows globally, the prevalence of AMD is expected to rise, thereby creating a surge in demand for innovative treatment solutions. The Macular Degeneration Treatment Market is experiencing significant growth due to advancements in medical technology, increasing awareness among patients, and the ongoing development of novel therapeutics. This article explores the current treatment options, emerging therapies, research directions, and market trends shaping the landscape of macular degeneration treatment.

Understanding Macular Degeneration

Macular degeneration is a chronic eye disorder that affects the macula, the central part of the retina responsible for sharp, detailed vision. The condition exists in two main forms:

Dry (Atrophic) AMD – Characterized by the gradual thinning of the macula, leading to slow vision loss.
Wet (Neovascular) AMD – Occurs when abnormal blood vessels grow under the retina, leaking fluid and blood, causing rapid and severe vision loss.

Dry AMD is more common, accounting for about 85–90% of cases, but wet AMD is responsible for the majority of cases with significant vision impairment.

Risk Factors

Several factors increase the risk of developing AMD, including:

Age – Primary risk factor; most common in people over 60.
Genetics – Family history and specific genetic mutations (e.g., CFH and ARMS2 genes).
Lifestyle – Smoking, obesity, and high-fat diet.
Race – More prevalent in Caucasians than other ethnic groups.
Cardiovascular health – Poor circulation and heart disease are associated with AMD.

Understanding these risk factors is essential for early diagnosis and preventive measures.

Diagnosis of Macular Degeneration

Accurate and timely diagnosis is crucial for managing AMD effectively. Common diagnostic methods include:

Visual Acuity Tests – Assess central vision clarity.
Amsler Grid Test – Helps detect visual distortions.
Dilated Eye Exam – Reveals retinal changes and drusen deposits.
Optical Coherence Tomography (OCT) – Provides cross-sectional images of the retina.
Fluorescein Angiography – Identifies leaking blood vessels in wet AMD.

These tools allow ophthalmologists to distinguish between dry and wet AMD and to monitor disease progression.

Current Treatment Options

1. Treatments for Dry AMD

There is currently no cure for dry AMD, but several strategies help slow its progression:

Nutritional Supplements (AREDS2 Formula)
A combination of antioxidants and minerals (vitamins C and E, zinc, copper, lutein, and zeaxanthin) shown to reduce the risk of progression in intermediate or advanced AMD.
Lifestyle Changes
Quitting smoking, adopting a diet rich in leafy greens and omega-3 fatty acids, maintaining a healthy weight, and controlling blood pressure.
Low Vision Aids
Devices like magnifiers, special glasses, and electronic systems that help patients cope with vision loss.

2. Treatments for Wet AMD

The primary treatment for wet AMD involves inhibiting abnormal blood vessel growth:

Anti-VEGF Injections
Drugs that block vascular endothelial growth factor (VEGF), a protein that promotes blood vessel growth. Commonly used medications include:
- Ranibizumab (Lucentis)
- Aflibercept (Eylea)
- Bevacizumab (Avastin) – Off-label use.
- Brolucizumab (Beovu)
- Faricimab (Vabysmo) – Dual-action VEGF/Ang-2 inhibitor
These are administered via intravitreal injections, often requiring monthly or bi-monthly visits, which can be burdensome for patients.
Photodynamic Therapy (PDT)
Combines a light-sensitive drug (verteporfin) with a laser to destroy abnormal blood vessels. Less commonly used today.
Laser Photocoagulation
Involves direct laser treatment to seal leaking vessels. Now largely replaced by anti-VEGF therapies due to the risk of damaging healthy retinal tissue.

Emerging and Investigational Treatments

The future of AMD treatment is promising, with several novel therapies under investigation:

1. Gene Therapy

Gene therapy aims to provide long-lasting treatment through a single injection that induces retinal cells to produce anti-VEGF agents internally. Key developments include:

RGX-314 (Regenxbio)
ADVM-022 (Adverum Biotechnologies)

These treatments are in clinical trials and show potential to reduce the treatment burden significantly.

2. Stem Cell Therapy

Stem cell-based treatments aim to regenerate or replace damaged retinal cells. Researchers are exploring the use of retinal pigment epithelial (RPE) cells derived from human embryonic stem cells.

Cellular Dynamics International and Astellas trials
OpRegen (Lineage Cell Therapeutics)

3. Complement Inhibitors

Targeting the complement system, which plays a role in inflammation and immune responses in dry AMD.

Pegcetacoplan (Syfovre) – FDA approved for geographic atrophy (advanced dry AMD).
Avacincaptad pegol (Izervay) – Another approved complement C5 inhibitor.

4. Oral Therapies and Eye Drops

Researchers are investigating oral drugs and topical formulations that could make treatment less invasive. These include:

PAN-90806 – A topical anti-VEGF drop.
Oral integrin inhibitors – Targeting cellular adhesion involved in neovascularization.

Artificial Intelligence in AMD Diagnosis and Management

AI and deep learning algorithms are revolutionizing ophthalmology. Key developments include:

Automated OCT Analysis – Detects early AMD changes.
Predictive Modeling – Forecasts disease progression and treatment outcomes.
Telemedicine Integration – Enhances remote screening and monitoring.

These technologies promise to improve access to care and reduce diagnostic delays.

Challenges in AMD Treatment

Despite significant advances, several challenges persist:

Treatment Burden – Frequent injections and follow-up visits affect adherence.
Cost and Accessibility – High cost of anti-VEGF drugs limits access in some regions.
Lack of Cure – Especially for dry AMD, treatments only slow progression.
Patient Awareness – Many patients do not seek treatment until advanced stages.

Addressing these challenges requires coordinated efforts in research, policy, and education.

Global Market Dynamics

The Macular Degeneration Treatment Market is expanding rapidly due to the aging population and growing awareness about eye health. Some key market drivers include:

Market Size and Forecast

Estimated global market value exceeded USD 8 billion in 2023
Expected to grow at a CAGR of 7–9% through 2032
Dominated by North America, followed by Europe and Asia-Pacific

Key Players

Roche (Genentech) – Lucentis and Vabysmo
Regeneron Pharmaceuticals – Eylea
Novartis – Beovu
Kodiak Sciences, Adverum Biotech, and Regenxbio – Emerging therapies

Market Trends

Biosimilars – Entry of affordable biosimilars like Byooviz (ranibizumab biosimilar)
Combination Therapies – Targeting multiple pathways simultaneously
Long-acting Implants – Port Delivery System (Susvimo) for sustained drug release

Patient Education and Support

Patient advocacy and support organizations play a vital role in managing AMD. Resources include:

The Macular Society
BrightFocus Foundation
American Macular Degeneration Foundation (AMDF)
Prevent Blindness

These organizations provide education, emotional support, and updates on clinical trials and new treatments.

Lifestyle and Preventive Strategies

Although macular degeneration cannot always be prevented, certain measures help reduce risk:

Regular Eye Exams – Especially after age 50
Healthy Diet – Rich in antioxidants, green leafy vegetables, and fish
Protect Eyes from UV Light – Use sunglasses outdoors
Avoid Smoking – Major modifiable risk factor

Early detection through routine screenings can preserve vision and delay progression.

Source:- https://www.databridgemarketresearch.com/reports/global-macular-degeneration-treatment-market

Conclusion

Macular degeneration, particularly AMD, represents a significant public health concern as populations age globally. While current treatments—especially anti-VEGF therapies—have revolutionized management, there remains an urgent need for long-term solutions, especially for dry AMD. Promising developments such as gene therapy, complement inhibitors, and regenerative medicine are reshaping the landscape. Simultaneously, the Macular Degeneration Treatment Market is thriving, driven by innovation, investment, and patient demand. Through continued research, technology integration, and patient-centered care, the future for individuals living with macular degeneration looks increasingly hopeful.

Other trending reaport:-

Global Dental Sutures Market - Industry Trends and Forecast to 2028

https://www.databridgemarketresearch.com/reports/global-dental-sutures-market

Global Change Control Management Software Market – Industry Trends and Forecast to 2028

https://www.databridgemarketresearch.com/reports/global-change-control-management-software-market

Global Meat Extract Market – Industry Trends and Forecast to 2029

https://www.databridgemarketresearch.com/reports/global-meat-extract-market

Global Plant Activators Market – Industry Trends and Forecast to 2030

https://www.databridgemarketresearch.com/reports/global-plant-activators-market

Global Lactobacillus Probiotic Ingredient for Animal Market – Industry Trends and Forecast to 2029

https://www.databridgemarketresearch.com/reports/global-lactobacillus-probiotic-ingredient-for-animal-market

Global Roll-Dried Starch Market – Industry Trends and Forecast to 2031